Immunoway
Best Tools for immunology Research

VcMMAE

Catalog No :	MC0559
Casno :	646502-53-6
Molecularformula :	C68H105N11O15
Purity :	99.11%
Target :	Drug-Linker Conjugates for ADC
Ic50 :	No data
In Vitro :	Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2].
In Vivo :	Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolonged tumor regression in xenograft models[2].
Fields :	VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
Specificity :	Target: Drug-Linker Conjugates for ADC. Fields: VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via th
Concentration :	99.11%
Storage Stability :	2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
Molecularweight :	1316.63
Cell Pathway :	Antibody-drug Conjugate/ADC Related

P References : [1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. [2]. Lisa Buckel, et al. Tumor radiosensitization

Products Images